Spyre Therapeutics Inc (SYRE) Implied Volatility Current

Tracking SYRE implied volatility helps you identify when options premiums on Spyre Therapeutics Inc are historically cheap or expensive, and where the best trades are hiding. Spyre Therapeutics Inc implied volatility reflects the market's expectation of future price movement: when SYRE IV rises, option premiums increase, creating opportunities for sellers, and when it drops, buyers can find cheaper contracts. Use our scanner to monitor Spyre Therapeutics Inc's implied volatility current levels in real time and filter for high-probability trades.

Implied volatility is derived from option prices using models like Black-Scholes and represents the annualized expected move of an underlying stock. For SYRE, tracking metrics like SYRE IV rank helps traders understand whether current implied volatility is historically high or low. IV rank compares today's reading against the past year's range — a high rank on SYRE signals rich premiums and potential mean-reversion, while a low rank may favor long options strategies.

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies.

In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

Premium sellers, directional traders, and spread builders all need the same starting point: a clear read on where SYRE implied volatility sits today versus where it has been. Our scanner ranks Spyre Therapeutics Inc implied volatility against its historical range, surfaces extremes in SYRE IV rank, and pairs every reading with the trades that exploit it. Stop guessing whether Spyre Therapeutics Inc IV is rich or cheap — measure it, then act on it.